Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrettâs esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
äŒæ¥ã³ãŒãCSTL
äŒç€ŸåCastle Biosciences Inc
äžå Žæ¥Jul 25, 2019
æé«çµå¶è²¬ä»»è
ãCEOãMaetzold (Derek J)
åŸæ¥å¡æ°761
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 25
æ¬ç€Ÿæåšå°505 S Friendswood Drive
éœåžFRIENDSWOOD
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·77546
é»è©±çªå·18667889007
ãŠã§ããµã€ãhttps://castlebiosciences.com/
äŒæ¥ã³ãŒãCSTL
äžå Žæ¥Jul 25, 2019
æé«çµå¶è²¬ä»»è
ãCEOãMaetzold (Derek J)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã